Tiger Brokers

BUZZ-Organon rises after US FDA clears first biosimilar for breast cancer

Reuters
Nov 17
BUZZ-Organon rises after US FDA clears first biosimilar for breast cancer

** Shares of healthcare firm Organon OGN.N rise 4.65% to $7.88 premarket

** Co and Shanghai Henlius Biotech say US FDA approves their breast cancer drug Poherdy

** The two companies' Poherdy first biosimilar to rival Roche's ROG.S Perjeta for HER2-positive breast cancer - OGN

** Co says drug to be used with other therapies for advanced or early-stage breast cancer; Organon to market in U.S - OGN

** Poherdy carries warnings for heart issues and birth defects; doctors advised to monitor patients, co says

** Up to last close, stock down ~50% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10